HUGroup Holdings (JP:4544)
:4544
Top Page
HUGroup Holdings
(4544)
Select Model
Select Model
Rating:55Neutral
Price Target:
¥3,268.00
▼(-12.36% Downside)
Action:ReiteratedDate:02/11/26
The score reflects improving fundamentals (return to profitability and moderate leverage) but still-thin margins and volatile free cash flow. Technicals are the main drag, with price below major moving averages and negative momentum indicators. Valuation is balanced by a solid dividend yield but offset by a high P/E.
Positive Factors
Business model & scale
HUGroup's core model—outsourced clinical lab testing—relies on long-term institutional relationships, centralized lab scale and a broad test menu. These structural attributes support durable volume-based economics, customer stickiness and cross-sell opportunities that sustain revenues over months.
Negative Factors
Thin profitability
Very slim EBIT and net margins limit the firm's ability to absorb cost shocks or invest while preserving returns. Persistent low margins constrain incremental earnings leverage from revenue growth, making sustained margin improvement essential for durable shareholder value.
Read all positive and negative factors
Positive Factors
Negative Factors
Business model & scale
HUGroup's core model—outsourced clinical lab testing—relies on long-term institutional relationships, centralized lab scale and a broad test menu. These structural attributes support durable volume-based economics, customer stickiness and cross-sell opportunities that sustain revenues over months.
Read all positive factors
HUGroup Holdings (4544) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥178.27B
Dividend Yield3.72%
Average Volume (3M)243.85K
Price to Earnings (P/E)8.7
Beta (1Y)0.40
Revenue Growth2.93%
EPS GrowthN/A
CountryJP
Employees5,295
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)95.82
Shares Outstanding57,491,623
10 Day Avg. Volume223,460
30 Day Avg. Volume243,853
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)1.14
Price to Sales (P/S)0.64
P/FCF Ratio7.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,370.00Price Target Upside17.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)114.88
Revenue Forecast (FY)¥257.81B
HUGroup Holdings Business Overview & Revenue Model
Company Description
H.U. Group Holdings, Inc., through its subsidiaries, provides laboratory testing products and services in Japan. The company offers lab testing and its related services to medical institutions; self-medication services; food, environment, and cosm...
How the Company Makes Money
HUGroup Holdings generates revenue primarily through its insurance premiums from life and non-life insurance policies. The company collects premiums from policyholders in exchange for coverage against various risks, which constitutes a significant...
HUGroup Holdings Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
66
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 247.71B | 243.03B | 236.95B | 260.91B | 272.94B | 223.02B |
| Gross Profit | 71.04B | 67.20B | 63.23B | 89.92B | 111.80B | 76.21B |
| EBITDA | 29.58B | 24.55B | 13.65B | 42.97B | 56.34B | 33.63B |
| Net Income | 5.57B | 2.76B | -7.55B | 15.68B | 29.60B | 17.47B |
Balance Sheet | ||||||
| Total Assets | 272.92B | 279.58B | 295.36B | 301.76B | 288.60B | 252.75B |
| Cash, Cash Equivalents and Short-Term Investments | 47.84B | 40.88B | 39.95B | 44.19B | 46.49B | 42.96B |
| Total Debt | 70.29B | 86.65B | 81.94B | 77.16B | 73.00B | 80.45B |
| Total Liabilities | 137.81B | 142.28B | 152.85B | 151.71B | 148.41B | 137.45B |
| Stockholders Equity | 135.02B | 137.12B | 142.50B | 150.05B | 140.18B | 115.31B |
Cash Flow | ||||||
| Free Cash Flow | 21.47B | 20.88B | 4.18B | 18.30B | 31.50B | 24.06B |
| Operating Cash Flow | 23.87B | 24.96B | 16.55B | 32.53B | 55.23B | 35.59B |
| Investing Cash Flow | 2.59B | -18.96B | -16.05B | -29.58B | -30.86B | -28.27B |
| Financing Cash Flow | -16.68B | -5.30B | -5.78B | -5.76B | -21.73B | -1.57B |
HUGroup Holdings Technical Analysis
Negative
3729.00
Price Trends
3151.11
Negative
3258.42
Negative
3323.16
Negative
Market Momentum
11.04
Negative
46.50
Neutral
21.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4544, the sentiment is Negative. The current price of 3729 is above the 20-day moving average (MA) of 3136.56, above the 50-day MA of 3151.11, and above the 200-day MA of 3323.16, indicating a bearish trend. The MACD of 11.04 indicates Negative momentum. The RSI at 46.50 is Neutral, neither overbought nor oversold. The STOCH value of 21.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4544.
HUGroup Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥214.53B | 15.29 | 9.53% | 2.19% | 8.90% | -3.71% | |
75 Outperform | ¥210.52B | 12.71 | ― | 2.35% | 7.55% | 16.01% | |
73 Outperform | ¥124.92B | 19.05 | ― | 0.25% | 9.97% | 16.27% | |
68 Neutral | ¥105.73B | 16.02 | ― | 2.47% | 1.86% | 1370.48% | |
55 Neutral | ¥178.27B | 8.69 | 2.65% | 3.72% | 2.93% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥68.06B | 77.03 | 5.76% | ― | 31.95% | -40.95% |
* Healthcare Sector Average
JP:4544
HUGroup Holdings
3,126.00
595.32
23.52%
JP:3360
Ship Healthcare Holdings
2,457.50
566.08
29.93%
JP:4480
Medley
2,071.00
-1,209.00
-36.86%
JP:3148
Create SD Holdings Co., Ltd.
3,310.00
371.99
12.66%
JP:6197
Solasto Corp.
1,116.00
685.68
159.34%
JP:9267
Genky DrugStores Co., Ltd.
4,020.00
1,112.86
38.28%
HUGroup Holdings Corporate Events
H.U. Group Cuts Profit Outlook but Holds Dividend Steady
Feb 9, 2026
H.U. Group Holdings has revised its full-year consolidated earnings forecast for the fiscal year ending March 31, 2026, trimming expected net sales to ¥250 billion and lowering projections for operating and ordinary profit. The changes reflec...
H.U. Group Lifts Nine-Month Profit, Confirms Dividend and Upgrades Full-Year Outlook
Feb 9, 2026
H.U. Group Holdings reported consolidated net sales of ¥186.7 billion for the nine months ended December 31, 2025, up 2.6% year on year, with operating profit surging 57.2% to ¥4.2 billion and profit attributable to owners of parent doub...
H.U. Group Names Goki Ishikawa as New President and Group CEO to Drive ‘H.U. 2030’ Plan
Jan 14, 2026
H.U. Group Holdings has appointed Managing Executive Officer Goki Ishikawa as Representative Executive Officer, President and Group CEO, effective April 1, 2026, succeeding current Chairman, President and Group CEO Shigekazu Takeuchi, who will rem...
H.U. Group Holdings Reports Strong Financial Performance for H1 2025
Nov 11, 2025
H.U. Group Holdings reported a significant improvement in its financial performance for the six months ended September 30, 2025, with a notable increase in operating profit by 143.2% year-on-year. The company’s net sales rose by 3.7%, indica...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.